Cross-Organ Differences Between IL-4Rα Blockade and IL-13-Selective Therapy in Immune-Priming and Barrier-Effector Compartments: Implications for Skin, Airway, and Gastrointestinal Diseases
Open Access
Abstract
Antibody therapies targeting the IL-4/IL-13 axis are used in type 2 inflammatory diseases affecting skin, airways, and gastrointestinal tissues. Clinical responses and biomarker behavior differ across organs, complicating trial interpretation and endpoint selection. We propose an IL-4Rα-centered framework that relates these differences to receptor-responsive cells, local cytokine supply, and the compartments sampled by each endpoint. Type I receptors (IL-4Rα/γc) support IL-4-dependent immune priming, including type 2 helper T-cell (Th2) differentiation and immunoglobulin E (IgE) class switching. Type II receptors (IL-4Rα/IL-13Rα1) respond to both IL-4 and IL-13 and are prominent in epithelial and mesenchymal effector programs. Selected immune populations also respond through Type II receptors. We connect receptor biology to organ-specific experimental mechanisms and clinical outcomes, distinguish within-cell receptor expression from tissue cellular composition, and consider IL-13Rα2 as a separate ligand-buffering regulator. These assignments are predominant tendencies rather than exclusive cellular localizations or validated treatment-selection rules. This approach links molecular, tissue, and clinical endpoints while avoiding claims of drug superiority based on cross-trial comparisons.Keywords
This publication has 111 references indexed in Scilit:
- The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsAmerican Journal of Clinical Dermatology, 2025
- Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Dermatology and Therapy, 2025
- Dupilumab in Adults With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2024
- Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E LevelsDermatology and Therapy, 2024
- Minimally Invasive Approaches to Diagnose and Monitor Eosinophilic GI DiseasesCurrent Allergy and Asthma Reports, 2024
- Binding, Neutralization and Internalization of the Interleukin-13 Antibody, LebrikizumabDermatology and Therapy, 2023
- Prevalence and Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, and Atopic DermatitisLung, 2023
- Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trialsInternational Forum of Allergy & Rhinology, 2022
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal PolyposisJAMA, 2016
- Transcriptional regulation by STAT6Immunologic Research, 2011